Wells Fargo & Company Crinetics Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$468 Billion
Q2 2025

A detailed history of Wells Fargo & Company transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 90,060 shares of CRNX stock, worth $4.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,060

Previous 91,494 1.57%

Holding current value

$4.05 Million

Previous $3.07 Million 15.58%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$25.56 - $33.76 $36,653 - $48,411	-1,434 Reduced 1.57%	90,060 $2.59 Million
Q1 2025 May 13, 2025	SELL	$32.3 - $53.15 $304,330 - $500,779	-9,422 Reduced 9.34%	91,494 $3.07 Million
Q4 2024 Feb 12, 2025	BUY	$50.66 - $60.69 $811,826 - $972,557	16,025 Added 18.88%	100,916 $5.16 Million
Q3 2024 Nov 13, 2024	BUY	$43.83 - $54.98 $524,688 - $658,165	11,971 Added 16.42%	84,891 $4.34 Million
Q2 2024 Aug 13, 2024	BUY	$42.12 - $51.91 $171,849 - $211,792	4,080 Added 5.93%	72,920 $3.27 Million
Q1 2024 May 10, 2024	BUY	$34.76 - $46.81 $1.66 Million - $2.24 Million	47,898 Added 228.72%	68,840 $3.22 Million
Q4 2023 Feb 09, 2024	SELL	$25.62 - $37.07 $790,377 - $1.14 Million	-30,850 Reduced 59.57%	20,942 $745,000
Q3 2023 Nov 13, 2023	BUY	$15.97 - $30.59 $122,282 - $234,227	7,657 Added 17.35%	51,792 $1.54 Million
Q2 2023 Aug 15, 2023	BUY	$15.73 - $23.6 $206,865 - $310,363	13,151 Added 42.44%	44,135 $795,000
Q1 2023 May 12, 2023	BUY	$15.31 - $21.1 $467,980 - $644,963	30,567 Added 7330.22%	30,984 $497,000
Q4 2022 Feb 13, 2023	SELL	$15.49 - $19.05 $8,658 - $10,648	-559 Reduced 57.27%	417 $7,000
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $9,869 - $12,191	-545 Reduced 35.83%	976 $19,000
Q2 2022 Aug 12, 2022	SELL	$16.49 - $27.64 $76,431 - $128,111	-4,635 Reduced 75.29%	1,521 $27,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $273,696 - $451,799	-15,959 Reduced 72.16%	6,156 $135,000
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $427,925 - $628,287	22,115 New	22,115 $628,000
Q2 2021 Aug 16, 2021	SELL	$15.9 - $21.15 $82,600 - $109,874	-5,195 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$13.3 - $17.55 $239,373 - $315,864	-17,998 Reduced 77.6%	5,195 $79,000
Q4 2020 Feb 09, 2021	BUY	$12.08 - $17.46 $40,516 - $58,560	3,354 Added 16.91%	23,193 $327,000
Q3 2020 Nov 05, 2020	SELL	$13.62 - $17.66 $5,679 - $7,364	-417 Reduced 2.06%	19,839 $311,000
Q2 2020 Aug 13, 2020	BUY	$13.04 - $23.23 $176,000 - $313,535	13,497 Added 199.69%	20,256 $355,000
Q1 2020 May 14, 2020	BUY	$11.52 - $26.46 $77,863 - $178,843	6,759 New	6,759 $99,000

Others Institutions Holding CRNX

# of Institutions

236

Shares Held

90M

Call Options Held

59.7K

Put Options Held

14.8K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.42B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Crinetics Pharmaceuticals, Inc. Transaction History